PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer-Results from the prospective PRAEGNANT registry
使用奥拉帕尼和他拉唑帕尼抑制PARP活性治疗HER2阴性晚期乳腺癌——来自前瞻性PRAEGNANT注册研究的结果
期刊:NPJ Breast Cancer
影响因子:7.6
doi:10.1038/s41523-026-00947-8
Hörner, Manuel; Hartkopf, Andreas; John, Nelson; Ziegler, Philipp; Häberle, Lothar; Uhrig, Sabrina; Goossens, Chloë; Amann, Niklas; Cieslik, Jan-Philipp; Tretschock, Lara M; Dannehl, Dominik; Deutsch, Thomas M; Dimpfl, Moritz; Ehlert, Max; Eichstädt, Kathleen; Englisch, Alexander; Köpke, Melitta B; Krückel, Annika; Link, Theresa; Müller, Annika; Reinhardt, Kristin; Roth, Jonas; Schäffler, Henning; Sych, Lea; Tauber, Nikolas; Tegeler, Christian M; Wichmann, Catharina; Banys-Paluchowski, Maggie; Princk, Henriette; Rody, Achim; Brucker, Sara Y; Ditsch, Nina; Ettl, Johannes; Fehm, Tanja; Hack, Carolin C; Hadji, Peyman; Hein, Alexander; Janni, Wolfgang W; Kolberg, Hans-Christian; Lüftner, Diana; Lux, Michael P; Müller, Volkmar; Taran, Florin-Andrei; Tesch, Hans; Wallwiener, Diethelm; Marmé, Frederik; Seitz, Stephan; Belleville, Erik; Michel, Laura L; Wallwiener, Markus; Fasching, Peter A; Schneeweiss, Andreas; Maurer, Christian